Neuroinflammation has been proposed as a common denominator in diverse central nervous system (CNS)-associated pathologies such as neurodegenerative diseases, acute injuries, metabolic, psychiatric and drug abuse induced disorders. In the CNS, microglia and astrocytes are the first cell types that respond and shape inflammatory and immune mediated insults. If these events cannot be controlled by natural antioxidants or anti-inflammatory mediators, autophagy and cellular death by apoptosis and/or necrosis may occur, contributing to the pathophysiology of diverse CNS pathologies.
Despite the efforts made to develop effective treatments, many preclinical and clinical studies have failed to show significant pharmacological effects of such treatments. In fact, there are no clinical anti-inflammatory therapies available to CNS pathologies, slow down their progression, or reduce their sequelae. This is probably because of reduced aqueous solubility of different drugs and their reduced access to CNS due to the Blood Brain Barrier and the efflux pumps that reduce drugs bioavailability in the brain. Another important aspect is the high incidence of adverse reactions induced by the doses used of available drugs and neurotoxic effects induced by the CNS local administration, limiting patient compliance to the treatment.
The aim of this Research Topic is to bring together recent discoveries of neuroinflammatory mechanisms involved in different brain-associated disorders, such as neurodegenerative diseases like Alzheimer's or Parkinson's, and traumatic brain injury, in order to uncover new avenues for potential pharmacological treatments. Moreover, this issue hopes to expose new pharmacological treatments or recent pharmaceutical developments to successfully deliver anti-inflammatory or neuroprotective drugs into the CNS, which could be translated to clinical settings.
This Research Topic invites submissions of different article types such as Original Research, Brief Research Report, Review, and Mini Review. Both human and animal models, and all respective state of the art experimental applications, will be welcome in this timely Research Topic. We encourage contributions addressing cellular and molecular aspects of neuroinflammatory processes relevant to the following topics:
• central nervous system pathologies;
• new pharmacological targets;
• the impact of novel drugs;
• repositioning of drugs;
• formulations or treatments on their pathophysiology.
Neuroinflammation has been proposed as a common denominator in diverse central nervous system (CNS)-associated pathologies such as neurodegenerative diseases, acute injuries, metabolic, psychiatric and drug abuse induced disorders. In the CNS, microglia and astrocytes are the first cell types that respond and shape inflammatory and immune mediated insults. If these events cannot be controlled by natural antioxidants or anti-inflammatory mediators, autophagy and cellular death by apoptosis and/or necrosis may occur, contributing to the pathophysiology of diverse CNS pathologies.
Despite the efforts made to develop effective treatments, many preclinical and clinical studies have failed to show significant pharmacological effects of such treatments. In fact, there are no clinical anti-inflammatory therapies available to CNS pathologies, slow down their progression, or reduce their sequelae. This is probably because of reduced aqueous solubility of different drugs and their reduced access to CNS due to the Blood Brain Barrier and the efflux pumps that reduce drugs bioavailability in the brain. Another important aspect is the high incidence of adverse reactions induced by the doses used of available drugs and neurotoxic effects induced by the CNS local administration, limiting patient compliance to the treatment.
The aim of this Research Topic is to bring together recent discoveries of neuroinflammatory mechanisms involved in different brain-associated disorders, such as neurodegenerative diseases like Alzheimer's or Parkinson's, and traumatic brain injury, in order to uncover new avenues for potential pharmacological treatments. Moreover, this issue hopes to expose new pharmacological treatments or recent pharmaceutical developments to successfully deliver anti-inflammatory or neuroprotective drugs into the CNS, which could be translated to clinical settings.
This Research Topic invites submissions of different article types such as Original Research, Brief Research Report, Review, and Mini Review. Both human and animal models, and all respective state of the art experimental applications, will be welcome in this timely Research Topic. We encourage contributions addressing cellular and molecular aspects of neuroinflammatory processes relevant to the following topics:
• central nervous system pathologies;
• new pharmacological targets;
• the impact of novel drugs;
• repositioning of drugs;
• formulations or treatments on their pathophysiology.
